ArticleFrontiers in pharmacology2026
SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unmet needs in hyperkinetic movement disorders (HMDs) within neuropsychiatric conditions include better treatments for HMDs in complex disorders like Huntington's disease (HD), Tourette syndrome and psychiatric comorbidities like tardive dyskinesia. The symptomatology of HD comprises chorea, a disabling movement disorder, neuropsychiatric disturbances and cognitive decline. VMAT2 inhibitors like tetrabenazine and its derivatives, as well as antipsychotics, are used for the treatment of HMDs but they may worsen motor function or the underlying neuropsychiatric symptoms. Specifically targeted therapies improving management of motor and non-motor symptoms with a safety profile suited for continued chronic treatment are needed. We describe here the novel mechanism of action of SOM3355, a CNS-permeant selective β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.